Allergy Therapeutics (Allergy Therapeutics) Short-Term Capital Lease Obligation

: $1.41 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.41 Mil.

Allergy Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Dec. 2022 ($1.38 Mil) to Jun. 2023 ($1.46 Mil) but then declined from Jun. 2023 ($1.46 Mil) to Dec. 2023 ($1.41 Mil).

Allergy Therapeutics's annual Short-Term Capital Lease Obligation increased from Jun. 2021 ($1.11 Mil) to Jun. 2022 ($1.62 Mil) but then declined from Jun. 2022 ($1.62 Mil) to Jun. 2023 ($1.46 Mil).

Allergy Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Allergy Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Capital Lease Obligation

1.80

1.11

1.62

1.46

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation																0.87	1.62	1.38	1.46	1.41

Allergy Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Allergy Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (Allergy Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AGY:UK HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.